Post Marketing Surveillance (PMS) of JARDIANCE in Chronic Heart Failure (CHF)

Boehringer Ingelheim

Status: Completed

Conditions: Heart Failure

Treatments: Drug: JARDIANCE®

Study type: Observational

Funder types: Industry

Identifiers

NCT05262764

1245-0286

Details and patient eligibility

About

Study objective is to investigate the safety and effectiveness of long-term daily use of JARDIANCE® Tablets in patients with chronic heart failure (CHF) under real-world use.

Enrollment: 1,200 patients

Sex: All

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patients with chronic heart failure (CHF) failure who are prescribed with JARDIANCE® Tablets in Japan
• Patients who have never been treated with Empagliflozin (including treatment for type 2 diabetes mellitus (T2DM)) before enrolment

Exclusion criteria

• None

Trial design

1,200 participants in 1 patient group

Patients with chronic heart failure (CHF)

Treatment:

Drug: JARDIANCE®